Phase I trial of weekly cabazitaxel with concurrent intensity modulated radiation therapy (IMRT) and androgen deprivation therapy (ADT) for the treatment of high-risk prostate cancer (PCa).
2014 ◽
Vol 32
(15_suppl)
◽
pp. e16009-e16009
2020 ◽
Vol 106
(5)
◽
pp. 939-947
2016 ◽
Vol 1
(4)
◽
pp. 300-309
◽
2010 ◽
Vol 28
(15_suppl)
◽
pp. TPS250-TPS250
2020 ◽
Vol 5
(3)
◽
pp. 396-403
◽
2017 ◽
Vol 99
(2)
◽
pp. E250-E251
2016 ◽
Vol 96
(2)
◽
pp. S33
◽
2018 ◽
Vol 102
(3)
◽
pp. S146
◽
2009 ◽
Vol 91
(2)
◽
pp. 237-242
◽
2018 ◽
Vol 102
(3)
◽
pp. e147-e148
◽